logo
Plus   Neg
Share
Email

AstraZeneca: Farxiga Meets Primary Endpoint In Phase III Trial - Quick Facts

AstraZeneca plc (AZN.L,AZN) reported positive results from the Phase III DAPA-HF trial, the first heart failure outcomes trial with an SGLT2 inhibitor in patients with and without type-2 diabetes. In the trial, Farxiga showed efficacy and safety data for the treatment of patients with heart failure on top of standard of care. The safety profile was consistent with the established safety profile of the medicine.

AstraZeneca said it plans to discuss the results of the DAPA-HF trial with health authorities as soon as possible.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Toyota Motor Corp. (TM) announced plans to invest $391 million at its pickup truck assembly plant in San Antonio, Texas. The investment is part of the Japanese automaker's plan to invest $13 billion in its U.S. operations over five years through 2021. The company said the investment will be used... Virgin Atlantic is set to challenge British Airways' dominance at London Heathrow as the carrier announced plans to fly to 84 new destinations from the airport when its third runway is opened. Chief Executive Shai Weiss said, "Heathrow has been dominated by one airline group for far too long. The... Walmart (WMT) on Wednesday announced that it is teaming up with Capital One to roll out two new credit cards designed to compete with cards from Apple and Amazon. The companies said the Capital One Walmart Rewards Credit Card Program with two new cards will launch on September 24. The program's Mastercard...
Follow RTT